Monthly Archives: September 2017

FTI DEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TechnipFMC plc and a Lead Plaintiff Deadline of October 2, 2017

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas, Houston Division on behalf of investors who purchased TechnipFMC plc (”TechnipFMC”) (NYSE: FTI) securities between April 27, 2017 and July 24, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/technipfmc-plc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) TechnipFMC had a material weakness in its internal control over rates used in the calculations of the foreign currency effects on certain of its engineering and construction projects; (ii) accordingly, the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, TechnipFMCs public statements were materially false and misleading at all relevant times.

If you suffered a loss in TechnipFMC, you have until October 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/technipfmc-plc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 476694

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 – RDY

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) (NYSE: RDY) between June 17, 2015 and August 10, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information, go to:

http://www.zlk.com/plsra-c/dr-reddys-laboratories-ltd?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.

If you suffered a loss in Dr. Reddy’s, you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476693

EVHC DEADLINE TUESDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Envision Healthcare Corporation and a Lead Plaintiff Deadline of October 3, 2017

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of investors who purchased Envision Healthcare Corporation (“Envision Healthcare”) (NYSE: EVHC) securities between March 2, 2015 and July 21, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/envision-healthcare-corporation?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Envision Healthcare’s subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in Envision Healthcare, you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/envision-healthcare-corporation?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 476695

AAOI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Applied Optoelectronics, Inc. and a Lead Plaintiff Deadline of October 4, 2017

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of investors who purchased Applied Optoelectronics, Inc. (“Applied Optoelectronics”) (NASDAQ: AAOI) securities between July 13, 2017 and August 3, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/applied-optoelectronics-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) a major customer was reducing its purchases of the Company’s 40G receivers; (2) the loss of this major customer’s business would have a severe negative impact on the Company’s financial performance; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in Applied Optoelectronics, you have until October 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/applied-optoelectronics-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 476696

DEADLINE TODAY – Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline – September 29, 2017

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ: IPCI) and certain of its officers, on behalf of shareholders who purchased IntelliPharmaCeutics securities between January 14, 2016 and July 26, 2016, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ipci.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) Intellipharmaceutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; (3) Intellipharmaceutics was not submitting sufficient data to support approval of the NDA; and (4) consequently, defendants’ statements about the Company’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On July 27, 2017, the FDA published a report revealing that “The safety information collected in the pharmacokinetic studies was of limited value…” Following this news, Intellipharmaceutics stock dropped over 45% to close at $1.36 per share on July 27, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ipci or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Intellipharmaceutics you have until September 29, 2017, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 476657

DEADLINE TODAY: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI)

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intellipharmaceutics International Inc. (NASDAQ: IPCI) who purchased shares between January 14, 2016 and July 26, 2017.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Intellipharmaceutics, you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/intellipharmaceutics-international-inc?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 476684

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Electronics for Imaging, Inc. Shareholders and a Lead Plaintiff Deadline of October 10, 2017 (EFII)

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Electronics for Imaging, Inc. (NASDAQ: EFII) who purchased shares between February 22, 2017 and August 3, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) the Company was improperly recognizing revenue; (2) the Company’s disclosure controls and procedures were not effective; (3) the Company’s internal control over financial reporting were not effective; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. On August 3, 2017, the Company announced that it would postpone its conference call to discuss second quarter 2017 preliminary results “in order to enable the Company to complete an assessment of the timing of recognition of revenue.” Electronics for Imaging is also assessing the effectiveness of its “current and historical disclosure controls and internal control over financial reporting.”

Shareholders have until October 10, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/electronics-for-imaging-inc?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 476685

The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Zillow Group, Inc. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (Z)

NEW YORK, NY / ACCESSWIRE / September 29, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zillow Group, Inc. (NASDAQ: Z) who purchased shares between February 12, 2016 and August 8, 2017. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Zillow’s co-marketing program did not comply with the Real Estate Settlement Procedures Act; and (2) as a result, Zillow’s public statements were materially false and misleading at all relevant times.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/zillow-group-inc?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 476686

Issuer Direct Upgrades Platform id.(TM) to Include Inline XBRL

Foreign Filers Reporting in IFRS Can Rely on Issuer Direct for all of Their SEC Reporting Requirements

MORRISVILLE, NC / ACCESSWIRE / September 29, 2017 / Issuer Direct Corporation (NYSE American: ISDR), an industry-leading communications and compliance company, today announced that its Cloud-based Platform id. disclosure system has been upgraded to include not only Inline XBRL but also all of the necessary regulatory taxonomies for foreign filers using International Financial Reporting Standards (“IFRS”).

Foreign filers with fiscal years ended on or after December 15, 2017 are required to begin reporting their financials in XBRL with the Securities and Exchange Commission (“SEC”) in early 2018. Issuer Direct’s Platform id. has adopted the new IFRS taxonomy into and with its new disclosure upgrade for Inline XBRL.

“Customer success is our number one priority at Issuer Direct, and to prepare for the upcoming SEC IFRS deadline, we are announcing that we have successfully on-boarded our first group of foreign filers utilizing our IFRS Inline XBRL tagging system,” said Brian Balbirnie, Chief Executive Officer for Issuer Direct. “We are fully prepared to handle our foreign reporting customers’ needs with our upgraded Inline XBRL system.”

For more information about the new IFRS rules for foreign filers, please click here.

Foreign filers that are reporting in IFRS that wish to take advantage of a special offer from Issuer Direct should contact us today to take our platform for a test drive. (http://info.issuerdirect.com/foreign-filers)

About Issuer Direct Corporation

Issuer Direct® is an industry-leading communications and compliance company focusing on the needs of corporate issuers. Issuer Direct’s principal platform, Platform id., empowers users by thoughtfully integrating the most relevant tools, technologies and services, thus eliminating the complexity associated with producing and distributing financial and business communications. Headquartered in RTP, NC, Issuer Direct serves more than 2,000 public and private companies in more than 18 countries. For more information, please visit www.issuerdirect.com.

Contact:

Brian R. Balbirnie
Issuer Direct Corporation
919-481-4000
brian.balbirnie@issuerdirect.com

Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Issuer Direct Corporation

ReleaseID: 476683

Le-Vel THRIVE Celebrates 5 Years of Multi-Level-Marketing Success

FRISCO, TX / ACCESSWIRE / September 29, 2017 / September 2017 marks 5 years since the beginning of Le-Vel and launch of THRIVE, a multi-level marketing (MLM) business and product line that promotes a premium and healthy lifestyle. The company began with one mission: to help people THRIVE, rather than just survive. Though the anniversary marks 5 years of Le-Vel THRIVE, the founders, Jason Camper and Paul Gravette, have committed nearly half a century to health and wellness. Camper and Gravette come from humble beginnings but turned an innovative idea into a billion-dollar business. The company’s mission since its foundation is to provide a premium product line that is easy to incorporate into your daily life and that will provide you with the nutrition you need to live a better life. The products are meant to provide energy, vitality, better cognitive functioning and an overall improved everyday life.

The company began in 2012 and lacked heavy funding. “We were the underdog, for sure,” stated the co-founders. The idea of a completely cloud-based company with no brick and mortar aspect was unheard of. Despite the lack of traditionalism, in Le-Vel’s first year, Camper and Gravette generated $10 million in revenue with the THRIVE product line. The company continued to steadily grow, with $100 million in revenue in its second year, $350 million in its third year, and $450 million in its fourth year. As of May 2017, Le-Vel earned over $1 billion in lifetime sales. July of 2017 was the company’s “largest revenue-generating month in Le-Vel’s history.”

The founders attribute their success to the THRIVERS; those that recognize the uniqueness of the company and that are passionate about not only the THRIVE premium line of products but the mission, too. THRIVERs are those who fully understand what leading a premium lifestyle is all about. “We are so fortunate to be stewards of a Movement that has attracted such a unique and amazing group of individuals, to be able to work with them to make an impact throughout the world and help millions live a life they deserve,” stated the co-founders. As of September 2017, the company has more than 6.5 million customers and independent Brand Promoters, better yet, THRIVERS, assisting in the growth of the company.

The company’s large community of THRIVERS not only unites to assist in Le-Vel’s mission for a healthier lifestyle but also to raise money for charity. In 2016, the company presented $255,000 to the National Breast Cancer Foundation (NBCF.) The money was collected via Derma Fusion Technology (DFT) sales. $5 from every purchase in the month of October in 2016 was collected to donate to NBCF. This donation reflects an ongoing partnership between Le-Vel THRIVE and the NBCF. “As a company dedicated to health and wellness, we feel strongly about playing a role in creating a reality in which this disease can be cured or prevented,” stated Gravette.

In continuance of their charitable actions, at the 2016 SUCCESS FROM HOME magazine launch event, Le-Vel released the limited edition Hoyt Derma Fusion Technology (DFTs.) Much like the fundraising efforts for the NBCF, $5 of every sale was presented to the Hoyt Foundation, which aims to build confidence and self-esteem in physically disabled youth in the United States. Efforts such as these are only a glance at Le-Vel’s determination to give back. Their charitable actions align with their mission to THRIVE in life.

Jason Camper, co-founder and co-CEO, was raised in Lubbock, Texas and attended Texas Tech University. It was during his time in college that he realized his passion for direct selling and nutrition. Camper worked in sales for almost a decade before he transitioned to the corporate side of the industry. During his initial years, Camper learned many aspects of the business and it was with that experience that he and his partner, Gravette, came up with the idea for a cloud-based business selling nutritional supplements.

Co-founder Paul Gravette was an experienced entrepreneur with proficiency in technology and communications. Camper and Gravette’s partnership spawned via the Internet, where they connected over their similar hopes for an innovative business model. In Le-Vel THRIVE’s infancy, Gravette and Camper shouldered most of the work. Camper oversaw operations and logistics, while Gravette used his sales expertise to network and grow the brand socially. Both founders interacted with brand promoters, conducted customer service, shipped products out, as well as any other minute-detailed work that goes into running a company.

Their hard work and long hours paid off as their company was brought to a new level. Le-Vel THRIVE is now a billion dollar multi-level marketing (MLM) company and the co-founders’ roles are somewhat different. Today, Gravette says the majority of his time is spent interacting with THRIVERS. And both co-founders are still profoundly dedicated to the mission of Le-Vel. Both Camper and Gravette are passionate about nutrition and are active in their daily life, amidst frequent work-related travel. Le-Vel’s 5-year anniversary demonstrates the success of what people often deem to exist no longer: the American Dream. “We weren’t heavily funded and we didn’t have a ton of things in our corner, which provided uncertainty that this company would be massively successful. But we did have a plan and the desire of two guys with full hearts and a set of goals and dreams with the determination in our eyes to go after them, no matter what anyone said or thought,” stated the founders. Both men have passions and dreams. Gravette himself enjoys design, while Camper enjoys golf. The human aspect of these men and their unwavering belief that THRIVE is helping millions of people make Le-Vel THRIVE’s success an inspiring story. The 5-year anniversary celebrates two men of humble beginnings with innovative minds and an ideology that, to achieve your dreams, you must dedicate hard work and a lot of elbow grease.

Le-Vel THRIVE’s 5 Year Growth: Innovative to Its Core

Le-Vel THRIVE started with just two men with an idea. As mentioned above, the co-founders dedicated themselves to every aspect of the business. In just 4 years’ time, the company could brag about more than 750,000 Brand Promoters and 4 million customers. Since then, the company has only grown. Le-Vel, innovative to its core, was the 2016 winner of the Direct Selling News Bravo Growth Award, which recognizes the largest year over year growth in the world in direct sales. The company demonstrated a 254% revenue surge at the time of recognition.

Le-Vel is the first virtual company in direct selling and sells not only THRIVE premium products but a lifestyle. Individuals find the Le-Vel THRIVE lifestyle appealing for many reasons: the founders, the products, the Brand Promoters, and the brand positioning. The multi-level-marketing aspect of Le-Vel utilizes a community of Brand Promoters that are passionate about the products they are selling. Moreover, the Brand Promoters are past customers that were so inspired by the products and mission, that they committed to being a part of it. Those selling Le-Vel THRIVE products are not, generally speaking, experienced in sales, but parents, teachers, nurses, etc. Take this testimonial from a father that struggled with fatigue as an example of the level of difference Le-Vel made in his life.

“Our story as a company is an example of dedicated individuals getting together, believing in themselves and their skill sets, and being willing and committed to doing things the way their gut says to do it, even if it’s not how others say it should be done,” stated the co-founders.

The technological aspect of Le-Vel is unlike many other businesses, especially MLM businesses. What’s important to note is that the company’s growth has been largely organic. The THRIVE testimonials of those engaging online are driving growth for the company. The entire company uses cloud technology to operate with a low overhead and fast reaction time. Most direct sales companies utilize a high concentration of sales teams, but this accumulates massive overhead for buildings, staffing, bills, etc. The multi-level-marketing concept of Le-Vel THRIVE utilizes less staff and cloud technology for more efficient operation management. The technology handles order management, commissions, customer and promoter support, team sales, etc. The teams use online webinars to connect and train digitally. Webinars may cover how the business works, how to become a Promoter, and more. See below for an example of an online training webinar.

The Founders

Co-founder Gravette built many online-only companies before “cloud” became a buzz word. Gravette stated that cloud-based technology lets Le-Vel THRIVE “reward our brand promoters and their customers with more because our overhead is a fraction of what most corporations have.” Compensation rewards range from cash, technology, and auto bonuses to lifestyle getaways with trips as a team to places like Las Vegas, Toronto, Cabo, Punta Cana, and more. In its five years, the company now maintains a full-time staff from all over the United States. The cloud-based structure allows Le-Vel to maneuver around limitations such as location-dependency.

Le-Vel THRIVE Brand Promoters and community utilize technology and social media to engage and support others. The company’s official social media pages are full of thousands of THRIVE testimonials from Brand Promoters and customers. Each post receives hundreds to thousands of words of encouragement and support. Their Facebook alone has grown to over 1 million fans, and, when combined with Gravette’s and Camper’s Facebook pages, the number balloons to over 3 million fans. The company has a global network of customers who are taking to social media to share their opinions of the THRIVE products. Since the beginning, the co-founders understood the power that technology would play in their business.

There is a high concentration of reviews online for Le-Vel THRIVE. Due to the success of the business originating primarily in the testimonials of THRIVERS, it is hard to ignore such powerful statements about the brand. For the full reviews, experiences, and comments visit the original pages.

“After using the products for several months, I wanted to share my Le Vel Thrive review with you. When I tried Thrive back in February, I remember first noticing that I was powering through my afternoon without the dreaded 3 pm slump. Then, I noticed being able to bounce out of bed at 5:30 am without any grogginess or hesitation. Within a week, my energy levels were back up, I was feeling less achy, less irritable, and happier in general.” – Lauren of seasaltandhome.com

“I personally completed the entire 8 week Thrive weight loss experience and I can honestly say that I was able to lose more weight and feel better than I have with any other diet plan I have tried. Better than the weight loss was the fact that I noticed a change in the way that I look at foods, now that I have a better understanding of how they impact the way I feel each day.” – Romney123

“Overall, I would recommend THRIVE to anyone willing to change a part of their lifestyle for more energy and better health. The THRIVE Lifestyle Mix was an easy addition to my mornings and kept me energized throughout the school day.” – goldenstatemom.com

“According to KU med nurse Caitlin Hogan, the answer is yes. “Thrive seems to be a safe choice for a multivitamin,” stated Hogan.” – http://www.butlercountytimesgazette.com/news/20170113/are-you-thriving

“It’s also worth noting that this company is constantly giving back. It’s owned by two guys that are totally down to earth and in it to make the world a better place. They’re constantly giving enormous sums of money to great charities. Plus they’ve developed a platform that gives everyone the power to build their own business. By being a customer, you’re helping a real family, and I love that”. – amagicalmess.com

Le-Vel THRIVE Premium Products 5 Year Growth

The first products offered by Le-Vel THRIVE were the THRIVE Premium Lifestyle Capsules and the THRIVE Premium Lifestyle Mix. Either of these products would have been ordered during the first order of Le-Vel history on September 18, 2012.

Le-Vel returned to the science lab to produce the THRIVE Premium Lifestyle Derma Fusion Technology (DFT.) Shortly after, the 8-week THRIVE Experience was born. The Experience promoted a simple methodology: three steps a day to live a healthier lifestyle. The simplicity of the THRIVE Experience appeals to many.

Following the DFT, Le-Vel introduced the THRIVE Plus line, which is a series of supplements that gives individuals more personalization for their routine. Le-Vel launched Balance, Move, Rest, Boost, Activate, Pure, Form, THRIVE K, Expand, Black Label (DFT), DFT Ultra, and DFT DUO. In the first 24 hours of the Black Label DFT product launch, it produced $1 million. Le-Vel also released a unique product unlike the other lines that is a collagen protein gel known as FORM. Beating the Black Label line, FORM generated $1 million in only two hours. Le-Vel’s science and dedication to its mission came together to release Expand, a nootropic capsule meant to support cognitive functioning. Perhaps one of the most successful launches was the limited release launch of DFT DUO, a weight management product which generated $7.5 million in 8 hours.

According to directsellingnews.com, Le-Vel THRIVE is constantly improving their standards for quality. “Company executives established a Scientific and Medical Advisory Board, which has more than 200 years of combined industry research in human nutrition and nutritional supplementation.” Le-Vel has commissioned multiple double-blind placebo-controlled safety studies and efficacy studies, as well as worked with Ohio State University to complete a statistical analysis on how to improve each future study, as well as, future products. Le-Vel THRIVE products focus on general health and wellness. The current product list is THRIVE M for men, THRIVE W for women, THRIVE Mix, THRIVE DFT, DFT Ultra, Black Label DFT, DFT DUO, Activate, Boost, Balance, Move, Rest, Form, THRIVE K, Pure, and Expand. Le-Vel THRIVE’s product diversity makes it unique. Not only does it offer derma fusion technology, but gels, capsules, shakes, and mixes. With Le-Vel THRIVE, no stone goes unturned. THRIVE K is specifically formulated for kids, while Expand is the first nootropic capsule meant to improve cognitive function and mental clarity.

Le-Vel THRIVE’s Major Accomplishments

Le-Vel THRIVE is the epitome of success as a start-up business by two entrepreneurs with an unconventional idea. Le-Vel released a 5-year anniversary memories video to commemorate its growth and success not only as a company but as a community.

https://le-vel.com/Lander/FiveYearAnniversary

The video highlights major accomplishments of the company, including its first sale on September 18, 2012, its $10 million revenue in sales in its first year, and its industry-changing DFT technology, which was the first derma-fusion technology. Additionally, in November of 2014, Success From Home released a magazine dedicated to Le-Vel and Le-Vel has since produced its own lifestyle magazine, titled Thrivin’. The video depicts the various retreats, getaways, and conferences that Le-Vel hosted for their THRIVE team. The company celebrated its expansion to Mexico, its billion-dollar total sales revenue, and its partnerships with athletes such as Amy Purdy and Emmitt Smith. Continuing its charitable movements, Le-Vel Thrive donated over $430,000 to AmeriCares for Hurricane Harvey victims.

To learn more about Le-Vel please visit: https://le-vel.com/
Le-Vel Facebook- https://www.facebook.com/LevelBrands/
Le-Vel Twitter- https://twitter.com/thelvlife/
Le-Vel LinkedIn- https://www.linkedin.com/company/3277978/

SOURCE: Le-Vel Thrive News

ReleaseID: 476622